Medical Pharmacology: Chapter 39 — Pharmacological Management of Coagulation Disorders -- Module 5 — Antiplatelet Therapy: From Aspirin to Novel Agents

Chapter 39 — Pharmacological Management of Coagulation Disorders — Module 5 — Antiplatelet Therapy: From Aspirin to Novel Agents

1. A 59-year-old man with no history of stroke or TIA (transient ischemic attack) had a STEMI (ST-elevation myocardial infarction) 4 months ago treated with primary PCI (percutaneous coronary intervention) and drug-eluting stent placement. He was discharged on clopidogrel 75 mg daily and aspirin 81 mg. He now returns with recurrent NSTEMI (non-ST-elevation myocardial infarction) confirmed by troponin elevation and new ST changes. Repeat coronary angiography reveals sub-acute in-stent thrombosis at the prior stent site. Pharmacogenomic testing sent at the time of the original admission returns with the result: CYP2C19*2/*2 homozygous — poor metabolizer. He weighs 88 kg and has no significant renal impairment. Which of the following represents the most appropriate adjustment to his antiplatelet regimen and the best rationale for the chosen agent?

A) Continue clopidogrel and add cilostazol 100 mg twice daily; cilostazol's PDE3 (phosphodiesterase type 3) inhibition raises platelet cAMP (cyclic AMP) independently of CYP2C19, augmenting residual clopidogrel effect; this combination is guideline-endorsed for overcoming clopidogrel resistance in CYP2C19 poor metabolizers after in-stent thrombosis.
B) Switch to vorapaxar 2.5 mg daily in addition to aspirin and clopidogrel; vorapaxar's PAR-1 (protease-activated receptor-1) antagonism is entirely CYP2C19-independent and provides the additional platelet pathway inhibition needed when clopidogrel fails in a poor metabolizer; this three-drug combination is the standard guideline recommendation after clopidogrel failure due to genotype.
C) Switch to prasugrel 10 mg daily or ticagrelor 90 mg twice daily; prasugrel requires only a single CYP oxidation step that is substantially less dependent on CYP2C19 than clopidogrel's two-step pathway, and ticagrelor is a direct-acting agent requiring no CYP bioactivation whatsoever; either agent will provide reliable, potent P2Y12 inhibition in this poor metabolizer who has now experienced the clinical consequence of inadequate clopidogrel bioactivation.
D) Increase clopidogrel to 150 mg daily with aspirin; the CURRENT-OASIS 7 trial demonstrated that doubled clopidogrel dosing in PCI patients reduces stent thrombosis by 42% compared to standard dose, and this benefit is specifically preserved in CYP2C19 poor metabolizers because the higher substrate load drives sufficient active metabolite generation even through dysfunctional CYP2C19*2 alleles.
E) Switch to aspirin 325 mg monotherapy; high-dose aspirin produces more complete COX-1 and COX-2 inhibition than 81 mg, eliminating both TXA2- and PGE2-mediated platelet activation pathways; this broader aspirin-mediated inhibition substitutes for the failed P2Y12 blockade in a CYP2C19 poor metabolizer and provides equivalent secondary prevention.

ANSWER: C

Rationale:

This patient has experienced the cardinal clinical consequence of CYP2C19 poor metabolizer status on clopidogrel — sub-acute in-stent thrombosis — confirming that clopidogrel bioactivation is inadequate at standard dosing. The appropriate response is to switch to a P2Y12 inhibitor whose efficacy is independent of CYP2C19 genotype. Prasugrel requires only a single CYP oxidation step (primarily CYP3A4 with minor CYP2C19 contribution) compared to clopidogrel's two steps, making it approximately three times more efficient in generating active thiol metabolite and substantially less sensitive to CYP2C19 loss-of-function alleles; this patient at 88 kg with no prior TIA or stroke meets none of the prasugrel contraindications or high-risk subgroups (prior TIA/stroke, age ≥75, weight <60 kg). Ticagrelor requires no CYP bioactivation at all — it is a direct-acting, reversible P2Y12 antagonist whose antiplatelet efficacy is entirely CYP2C19-independent; it is an equally appropriate choice. Both the TAILOR-PCI trial and international expert consensus guidelines support switching CYP2C19 poor metabolizers from clopidogrel to either prasugrel or ticagrelor.

Option A: Option A is incorrect: cilostazol is not guideline-endorsed as a clopidogrel adjunct for overcoming CYP2C19-related resistance after in-stent thrombosis; cilostazol has been used as a third antiplatelet agent in some East Asian PCI populations for stent optimization, but it does not substitute for adequate P2Y12 inhibition and would not address the fundamental inadequacy of clopidogrel bioactivation in this poor metabolizer.
Option B: Option B is incorrect: vorapaxar adds PAR-1 inhibition but does not address the absent P2Y12 pathway inhibition; stent thrombosis is driven primarily by ADP-mediated platelet activation at the stent surface, which requires P2Y12 blockade, not supplemental thrombin pathway inhibition; vorapaxar added to continued clopidogrel in a poor metabolizer still leaves P2Y12 inadequately blocked.
Option D: Option D is incorrect: doubled clopidogrel dosing does not overcome homozygous CYP2C19*2 poor metabolizer status; the CURRENT-OASIS 7 trial showed benefit from doubled-dose clopidogrel in the general PCI population, but this benefit does not extend to patients with severely impaired CYP2C19 function where substrate dose alone cannot compensate for absent enzyme activity; guidelines specifically recommend switching genotype, not dose-escalating clopidogrel, in poor metabolizers.
Option E: Option E is incorrect: high-dose aspirin cannot substitute for P2Y12 inhibition after coronary stent placement; aspirin and P2Y12 inhibition target distinct activation pathways; reducing DAPT to aspirin monotherapy within months of drug-eluting stent placement places this patient at extreme risk for recurrent stent thrombosis.

2. A 67-year-old man who received a drug-eluting stent 5 months ago for an NSTEMI (non-ST-elevation myocardial infarction) has been maintained on prasugrel 10 mg daily and aspirin 81 mg without incident. He presents to the emergency department with a 45-minute episode of right-hand weakness and dysarthria that fully resolved; neurological examination is now normal and MRI-DWI (diffusion-weighted imaging) shows no acute infarct. Neurology diagnoses a transient ischemic attack (TIA) in the left MCA (middle cerebral artery) territory. He has no atrial fibrillation on monitoring. His cardiologist is urgently consulted regarding his antiplatelet regimen. Which of the following represents the correct and most urgent management change to his P2Y12 inhibitor?

A) Prasugrel must be discontinued immediately; a history of TIA constitutes an absolute contraindication to prasugrel based on net harm demonstrated in the TRITON-TIMI 38 trial, where patients with prior stroke or TIA receiving prasugrel had a marked excess of intracranial hemorrhage that outweighed ischemic benefit; he should be transitioned to clopidogrel or ticagrelor to maintain P2Y12 inhibition while eliminating the intracranial hemorrhage risk specific to prasugrel.
B) Prasugrel should be continued at the current dose because TIA occurring more than 3 months after the initiating neurological event no longer constitutes a contraindication; the TRITON-TIMI 38 prasugrel restriction applies only to TIA events occurring within 90 days of initiating prasugrel therapy, not to new TIA events arising during maintenance therapy.
C) Prasugrel should be dose-reduced to 5 mg daily; the prasugrel prescribing information permits dose reduction to 5 mg in patients who develop TIA after stent placement, providing a safer maintenance level while preserving the superior P2Y12 inhibition over clopidogrel that reduces stent thrombosis risk; this compromise avoids both the loss of P2Y12 efficacy from switching to clopidogrel and the intracranial hemorrhage risk of full-dose prasugrel.
D) Prasugrel should be replaced by vorapaxar 2.5 mg daily; vorapaxar's PAR-1 antagonism does not carry the intracranial hemorrhage risk associated with prasugrel in TIA patients, and its addition to aspirin provides sufficient antiplatelet coverage for the post-stent period while the thrombin pathway blockade offers complementary cerebrovascular protection.
E) Prasugrel should be temporarily held for 30 days pending completion of the TIA workup; if no cardioembolic source is identified and MRI confirms no established infarct, prasugrel can be safely restarted at 10 mg daily because the TRITON-TIMI 38 contraindication was established in a population with prior (not incident) TIA and does not apply to patients who develop their first TIA while already on the drug.

ANSWER: A

Rationale:

Prior stroke or TIA is an absolute contraindication to prasugrel, and this contraindication applies regardless of when the event occurred relative to prasugrel initiation — whether the TIA preceded prasugrel start or arises during maintenance therapy. In the TRITON-TIMI 38 trial, patients with prior stroke or TIA who received prasugrel demonstrated net clinical harm: excess intracranial hemorrhage substantially outweighed any ischemic benefit, producing a negative net clinical outcome in this subgroup. The contraindication is listed in prasugrel's FDA-approved prescribing information as a boxed warning and formal contraindication without a time-qualification caveat. The correct and urgent management is to discontinue prasugrel and transition to an alternative P2Y12 inhibitor that does not carry this specific intracranial hemorrhage risk: clopidogrel (standard of care with an established safety profile in cerebrovascular disease) or ticagrelor (which does not carry the same TIA/stroke contraindication as prasugrel). A loading dose of the chosen alternative should be given at the time of the switch to ensure immediate P2Y12 coverage given the very high stent thrombosis risk of stopping any P2Y12 inhibitor at only 5 months post-DES.

Option B: Option B is incorrect: the prasugrel contraindication for TIA does not have a 90-day lookback window; it is an absolute contraindication based on any history of TIA or stroke, including newly developed TIA during maintenance therapy; there is no time-qualification in the prescribing information.
Option C: Option C is incorrect: dose reduction to 5 mg is indicated for patients weighing less than 60 kg to reduce bleeding risk, not for patients who develop TIA; reducing the dose does not eliminate the intracranial hemorrhage risk that constitutes the contraindication.
Option D: Option D is incorrect: vorapaxar is absolutely contraindicated in any history of stroke or TIA (as stated in its prescribing information with a boxed warning); this patient's new TIA makes vorapaxar equally contraindicated; it cannot substitute for prasugrel in this setting.
Option E: Option E is incorrect: the prasugrel contraindication is not limited to prior (pre-drug) TIA; a TIA occurring at any time while on prasugrel creates the contraindication for continued use; the drug must be stopped, not held pending workup; and the TRITON-TIMI 38 finding was applied to any stroke/TIA history regardless of timing.

3. A 72-year-old woman with persistent atrial fibrillation (AF) and a CHA₂DS₂-VASc score of 4 has been on warfarin (target INR 2.0–3.0) for stroke prevention for 3 years. She presents with an NSTEMI (non-ST-elevation myocardial infarction) and undergoes PCI (percutaneous coronary intervention) with drug-eluting stent placement. She tolerates the procedure without complication and her INR on the day of PCI is 2.4. The treatment team debates her post-discharge antithrombotic regimen. One team member argues for continuing warfarin plus adding clopidogrel, while another recommends switching to apixaban plus clopidogrel. A third suggests triple therapy indefinitely. The patient's renal function and liver function are normal, and there is no history of mechanical heart valves or antiphospholipid syndrome. Which of the following best summarizes the evidence-based antithrombotic strategy for this patient following an initial brief triple therapy period?

A) Warfarin plus clopidogrel is the preferred long-term strategy because warfarin's decades-long track record in AF stroke prevention and the ability to monitor anticoagulant effect with INR provide superior stroke protection compared to apixaban in elderly women; DOACs (direct oral anticoagulants) have not been studied in elderly AF patients with recent PCI and should be reserved for patients who cannot tolerate warfarin monitoring.
B) Triple therapy with warfarin, aspirin, and clopidogrel should be continued indefinitely because the patient's CHA₂DS₂-VASc score of 4 indicates very high stroke risk, and the risk of stent thrombosis in the first year after drug-eluting stent placement justifies maintaining all three antithrombotic components; the high ischemic risk outweighs the bleeding risk from triple therapy in this patient.
C) Apixaban plus aspirin without clopidogrel is the preferred regimen because the AUGUSTUS trial demonstrated that P2Y12 inhibitors added to OAC (oral anticoagulant) plus aspirin did not reduce stent thrombosis; dropping the P2Y12 inhibitor while maintaining both apixaban and aspirin provides AF stroke prevention and sufficient antiplatelet coverage with lower bleeding risk than full triple therapy.
D) Apixaban plus clopidogrel without aspirin is the preferred strategy, supported by the AUGUSTUS trial in which apixaban produced significantly less bleeding than warfarin-based therapy without compromising ischemic outcomes, and in which adding aspirin to OAC plus P2Y12 inhibitor doubled clinically relevant bleeding without reducing ischemia; a DOAC is preferred over warfarin and aspirin should be omitted beyond the brief initial triple therapy window.
E) Warfarin plus aspirin without a P2Y12 inhibitor is preferred because aspirin provides sufficient post-PCI antiplatelet protection through COX-1 inhibition and TXA2 suppression, and the addition of warfarin addresses AF stroke risk; P2Y12 inhibitors are required only for the first 4 weeks after stent placement and can then be safely omitted, leaving aspirin plus anticoagulation as a simpler two-drug regimen.

ANSWER: D

Rationale:

This patient has two concurrent indications for antithrombotic therapy: AF stroke prevention (requiring anticoagulation) and post-PCI stent thrombosis prevention (requiring antiplatelet therapy). The AUGUSTUS trial (n = 4,614) directly addressed the comparative safety of different antithrombotic combinations in exactly this population. Key findings were: (1) apixaban-based therapy produced significantly less clinically relevant or major bleeding than warfarin-based therapy without significant differences in ischemic outcomes, establishing DOAC preference over warfarin for eligible AF-PCI patients; (2) adding aspirin to OAC plus P2Y12 inhibitor doubled clinically relevant bleeding (16.1% vs. 9.0%) without reducing the composite ischemic endpoint, providing strong evidence to omit aspirin after the initial brief triple therapy period. This patient has normal renal and hepatic function, no mechanical valve, and no antiphospholipid syndrome — all conditions that would preclude DOAC use — making her an ideal candidate for apixaban. The recommended long-term strategy is therefore apixaban plus clopidogrel without aspirin.

Option A: Option A is incorrect: the AUGUSTUS trial included elderly AF patients with recent PCI and demonstrated apixaban superiority over warfarin in this exact population; DOACs are not investigational in elderly AF-PCI patients and are the preferred agents per current ACC/AHA guidelines.
Option B: Option B is incorrect: indefinite triple therapy is not supported; AUGUSTUS demonstrated that aspirin doubles bleeding without reducing ischemia in the maintenance phase; triple therapy is recommended only for the initial 1 to 4 weeks of highest stent thrombosis risk.
Option C: Option C is incorrect: AUGUSTUS demonstrated the importance of maintaining the P2Y12 inhibitor (not aspirin) as the antiplatelet component; OAC plus P2Y12 without aspirin — not OAC plus aspirin without P2Y12 — is the recommended dual therapy strategy; dropping P2Y12 in favor of aspirin plus OAC reverses the evidence-based component selection.
Option E: Option E is incorrect: P2Y12 inhibition is required for substantially longer than 4 weeks after drug-eluting stent placement; current guidelines recommend at least 6 to 12 months of P2Y12 inhibition post-DES depending on clinical context; warfarin plus aspirin without P2Y12 provides inadequate stent thrombosis protection beyond the immediate post-PCI period.

4. A 63-year-old man undergoes PCI (percutaneous coronary intervention) for an NSTEMI (non-ST-elevation myocardial infarction) with a large thrombus burden identified at angiography. Bail-out eptifibatide is administered as a double bolus of 180 mcg/kg followed by a 2 mcg/kg/min infusion. His pre-procedure platelet count was 214,000/mcL. A routine platelet count drawn 3 hours after eptifibatide initiation returns at 19,000/mcL. He has no current bleeding and is hemodynamically stable. He has no prior exposure to any GP IIb/IIIa inhibitor, heparin, or low-molecular-weight heparin. Which of the following represents the most appropriate immediate management, and correctly addresses both the diagnostic and therapeutic priorities?

A) Continue eptifibatide at the current infusion rate and administer a platelet transfusion of one apheresis unit immediately; the thrombocytopenia is a predictable dose-dependent effect of GP IIb/IIIa inhibition that does not require drug cessation; platelet transfusion restores the count and the infusion should be continued for the full planned 18 to 24 hours to maintain stent patency.
B) Stop the eptifibatide infusion immediately and also stop heparin pending exclusion of concurrent HIT (heparin-induced thrombocytopenia); confirm the platelet count by repeating in a citrate tube to exclude pseudothrombocytopenia; if the thrombocytopenia is confirmed and there is no serious bleeding, monitor closely; administer platelet transfusion if there is significant bleeding or an urgent invasive procedure is required; do not rechallenge with eptifibatide.
C) Stop eptifibatide and administer fresh frozen plasma (FFP) immediately to replenish the coagulation factors consumed during the thrombocytopenic state; platelet transfusion is contraindicated in GP IIb/IIIa inhibitor thrombocytopenia because transfused platelets will be inhibited by circulating eptifibatide and will trigger immune complex formation, worsening the thrombocytopenic response.
D) Stop eptifibatide and administer intravenous methylprednisolone 1 g immediately; GP IIb/IIIa inhibitor thrombocytopenia is a corticosteroid-responsive immune reaction analogous to immune thrombocytopenic purpura (ITP), and high-dose steroids are the first-line treatment that will restore the platelet count within 24 to 48 hours; platelet transfusion should be reserved for counts below 10,000/mcL.
E) Continue eptifibatide but reduce the infusion rate by 50%; the thrombocytopenia reflects dose-dependent receptor saturation at standard infusion rates; halving the infusion rate will reduce receptor occupancy sufficiently to allow platelet count recovery while maintaining adequate P2Y12-level antiplatelet protection for the recently placed stent.

ANSWER: B

Rationale:

Acute profound thrombocytopenia within hours of GP IIb/IIIa inhibitor initiation — even on first exposure — is a recognized class-specific immune-mediated complication and constitutes a medical emergency requiring immediate drug cessation. The mechanism involves naturally occurring antibodies recognizing LIBS (ligand-induced binding site) neoepitopes exposed on GP IIb/IIIa when the inhibitor occupies the receptor. The first step after identifying the low platelet count is to verify it is real: pseudothrombocytopenia (platelet clumping due to EDTA in standard collection tubes) is excluded by repeating the count in a citrate-anticoagulated tube. Once confirmed, eptifibatide must be stopped immediately. Heparin should also be stopped pending exclusion of concurrent HIT, as both drugs were given and HIT antibody testing may take hours; HIT and GP IIb/IIIa inhibitor thrombocytopenia can coexist. Because this patient has no current bleeding and is hemodynamically stable at a platelet count of 19,000/mcL, monitoring without immediate transfusion is reasonable; the thrombocytopenia typically begins to resolve within 24 to 48 hours of stopping the drug. Platelet transfusion is reserved for patients with serious bleeding or those requiring urgent invasive procedures; it is not routinely given for asymptomatic profound thrombocytopenia. The patient should never be rechallenged with the offending GP IIb/IIIa inhibitor.

Option A: Option A is incorrect: continuing eptifibatide in the setting of GP IIb/IIIa inhibitor-induced thrombocytopenia is contraindicated; the drug is the causative agent and must be stopped; platelet transfusion administered while the drug is still infusing will be of limited benefit as circulating eptifibatide will occupy GP IIb/IIIa on transfused platelets.
Option C: Option C is incorrect: FFP is not indicated for thrombocytopenia (it does not contain platelets and does not correct platelet counts); platelet transfusion is not contraindicated in GP IIb/IIIa inhibitor thrombocytopenia — it is the appropriate treatment when bleeding occurs or a procedure is required; transfused platelets do become inhibited by circulating eptifibatide but do add uninhibited platelet mass as drug concentrations fall.
Option D: Option D is incorrect: high-dose corticosteroids are not the established first-line treatment for GP IIb/IIIa inhibitor thrombocytopenia; the primary intervention is drug cessation; unlike ITP, this reaction is not steroid-responsive in the same predictable manner and steroids are not part of standard management guidelines for this drug reaction.
Option E: Option E is incorrect: dose reduction does not treat the immune-mediated mechanism; the thrombocytopenia is not dose-dependent receptor saturation but an antibody-mediated immune reaction that will persist as long as the drug occupies the receptor; the correct intervention is complete cessation.

5. A 76-year-old woman with stable coronary artery disease undergoes elective PCI (percutaneous coronary intervention) with a new-generation drug-eluting stent for a high-grade LAD (left anterior descending artery) stenosis. Her pre-procedure creatinine clearance (CrCl) is 28 mL/min, hemoglobin is 10.2 g/dL, white blood cell count is 8.7 × 10⁹/L, and she had a spontaneous upper GI bleed requiring hospitalization 14 months ago. Her PRECISE-DAPT score is calculated at 32. She has no prior ACS (acute coronary syndrome) and the procedure is uncomplicated. The interventional cardiologist discusses post-procedure DAPT (dual antiplatelet therapy) duration with the patient. Which of the following represents the most appropriate DAPT duration recommendation for this patient and the correct application of the PRECISE-DAPT score?

A) Standard 12-month DAPT is required regardless of bleeding risk score because drug-eluting stents mandate a minimum 12-month DAPT period to prevent late in-stent thrombosis; the PRECISE-DAPT score identifies high bleeding risk patients but cannot override the minimum duration requirement established by regulatory approval of drug-eluting stents.
B) Extended 24-month DAPT is indicated because this patient's advanced age, anemia, and CKD (chronic kidney disease) collectively indicate that her ischemic risk outweighs her bleeding risk; the PRECISE-DAPT score of 32 identifies patients who need longer, not shorter, DAPT to compensate for their higher baseline platelet reactivity associated with CKD.
C) Short-course DAPT of 3 to 6 months is the appropriate recommendation; a PRECISE-DAPT score of 32 — which exceeds the validated threshold of 25 — identifies this patient as at high bleeding risk; for patients with high PRECISE-DAPT scores receiving new-generation drug-eluting stents in the elective (non-ACS) setting, shortened DAPT of 3 to 6 months is the guideline-supported strategy that reduces bleeding risk while accepting the modestly higher ischemic risk associated with shorter P2Y12 inhibition.
D) DAPT should be omitted entirely after this elective PCI; this patient's PRECISE-DAPT score of 32, combined with her recent GI bleed and advanced CKD, represents an absolute contraindication to any P2Y12 inhibitor use; aspirin monotherapy alone is sufficient for elective stent protection when bleeding risk is very high.
E) The PRECISE-DAPT score does not apply to elective PCI patients; it was validated only in ACS populations where baseline platelet reactivity is higher; for stable coronary artery disease patients undergoing elective stenting, standard 6-month DAPT is the correct default without score-based adjustment, regardless of calculated PRECISE-DAPT value.

ANSWER: C

Rationale:

The PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy) score was specifically developed and validated to predict bleeding risk at 12 months in patients undergoing coronary stent implantation with planned DAPT, incorporating five variables: age, creatinine clearance, hemoglobin, white blood cell count, and prior spontaneous bleeding. A score of 25 or above identifies patients at high bleeding risk for whom shortened DAPT (3 to 6 months) is the preferred strategy, particularly when a new-generation drug-eluting stent has been implanted. This patient's score of 32 — driven by her advanced age, severely reduced CrCl of 28 mL/min, low hemoglobin, and prior spontaneous GI bleed — clearly exceeds the threshold. In the elective (non-ACS) setting with a new-generation DES (which has lower rates of late stent thrombosis than older-generation stents), the guideline consensus is that the bleeding risk reduction from shortened DAPT of 3 to 6 months outweighs the incremental ischemic risk compared to standard 6 to 12 months. The PRECISE-DAPT score was validated in both ACS and stable CAD populations undergoing PCI.

Option A: Option A is incorrect: 12-month DAPT is not an immutable minimum requirement for all DES patients; current guidelines explicitly support shorter DAPT duration (1 to 3 months acceptable, 3 to 6 months standard for high bleeding risk) in patients receiving new-generation DES when bleeding risk is high; regulatory approval of DES does not mandate 12 months of DAPT for all patients.
Option B: Option B is incorrect: the PRECISE-DAPT score predicts bleeding risk and a score above 25 supports shorter, not longer, DAPT; CKD and anemia increase bleeding risk (not ischemic risk equivalently), and the score correctly captures these as indications for shortened therapy.
Option D: Option D is incorrect: a high PRECISE-DAPT score does not constitute an absolute contraindication to P2Y12 inhibitor use; after coronary stent placement, some duration of dual antiplatelet therapy is required to prevent stent thrombosis; DAPT omission is not the recommended strategy at any PRECISE-DAPT score level.
Option E: Option E is incorrect: the PRECISE-DAPT score was developed and validated in both ACS and stable CAD populations undergoing PCI; it is not restricted to ACS patients; its application is appropriate for this elective PCI patient.

6. A 55-year-old man who received a drug-eluting stent 7 weeks ago for an NSTEMI (non-ST-elevation myocardial infarction) is on ticagrelor 90 mg twice daily and aspirin 81 mg. He now presents with symptomatic cholelithiasis and his surgeon recommends elective laparoscopic cholecystectomy. The surgeon asks the cardiologist how to manage ticagrelor around the procedure and whether surgery is safe at this interval post-stent. Which of the following most accurately characterizes the perioperative antiplatelet management and the risk considerations at 7 weeks post-DES?

A) Ticagrelor can be continued through surgery without interruption because laparoscopic cholecystectomy is a low-bleeding-risk procedure in which the surgical field is controlled by electrocautery; the 5-day pre-operative hold recommendation applies only to open abdominal, cardiac, and orthopedic procedures; P2Y12 inhibitor continuation during laparoscopic surgery is guideline-supported when stent placement occurred within 6 months.
B) Ticagrelor should be held 3 days before surgery rather than 5 days because its reversible binding mechanism allows faster platelet function recovery than irreversible thienopyridines; at 3 days post-last-dose, sufficient platelet function recovery has occurred for safe laparoscopic hemostasis, and the shortened hold reduces the window of stent thrombosis vulnerability.
C) Surgery should proceed without any antiplatelet hold; at 7 weeks post-DES, stent endothelialization is complete and the risk of stent thrombosis from a brief antiplatelet interruption is negligible; current guidelines support elective surgery at 6 weeks post-DES without antiplatelet modification for procedures that can be performed under aspirin continuation.
D) The elective cholecystectomy should be deferred until at least 6 months post-DES placement; at 7 weeks, the stent is in its highest-risk period for thrombosis during any P2Y12 inhibitor interruption; guideline consensus recommends deferring all non-emergent non-cardiac surgery until a minimum of 6 months of DAPT has been completed to allow adequate stent endothelialization.
E) Ticagrelor should be held 5 days before the planned surgery per standard perioperative guidelines; aspirin should generally be continued throughout, as the bleeding risk contribution of aspirin alone in laparoscopic surgery is low and continuation reduces the period of completely unprotected stent exposure; at 7 weeks post-DES, the stent remains in a high-risk period and the surgical team and cardiologist should discuss whether the elective procedure can be deferred until the higher-risk early post-stent window has passed.

ANSWER: E

Rationale:

Ticagrelor's recommended pre-operative hold for elective surgery is 5 days, reflecting the time needed for sufficient platelet function recovery given the drug's potent, near-complete P2Y12 inhibition even though the binding is reversible. Aspirin should generally be continued perioperatively when possible, as it provides partial antiplatelet protection (COX-1/TXA2 inhibition) during the P2Y12 inhibitor hold interval, and its bleeding contribution in laparoscopic cholecystectomy is typically manageable. The critical additional clinical judgment required in this case is whether elective surgery is appropriate at only 7 weeks post-DES. Drug-eluting stent endothelialization typically takes 3 to 6 months, and the risk of stent thrombosis during P2Y12 inhibitor interruption is highest in the first 3 to 6 months. Current guidelines generally recommend deferring elective non-cardiac surgery until 6 months post-DES when feasible, recognizing that the first 3 months represent the highest-risk window. At 7 weeks post-stent, this patient is still within the elevated-risk period; if the cholecystectomy can be deferred until 6 months of completed DAPT, that is the preferred approach. If surgery cannot be deferred (e.g., symptomatic progression, complications), the cardiology and surgical teams must co-manage with explicit discussion of stent thrombosis risk during the hold.

Option A: Option A is incorrect: the 5-day ticagrelor hold applies to any surgery where significant bleeding could occur, not only to open or major procedures; laparoscopic cholecystectomy does involve potential for significant bleeding and requires the standard pre-operative P2Y12 hold.
Option B: Option B is incorrect: the guideline-recommended hold for ticagrelor is 5 days, not 3 days; a 3-day hold has been proposed in some contexts but is not the current standard recommendation for high-bleeding-risk surgery.
Option C: Option C is incorrect: stent endothelialization is not complete at 7 weeks for modern drug-eluting stents, which elute antiproliferative drugs that deliberately delay re-endothelialization; 6 weeks post-DES remains within the high-risk window for stent thrombosis during antiplatelet interruption; deferral of elective surgery is the preferred approach.
Option D: Option D is incorrect: while deferring to 6 months is the preferred guideline recommendation, the statement that all non-emergent surgery must wait until 6 months is overly absolute; current guidelines use "at least 3 months" for bare-metal stents (now rarely used) and "at least 6 months" as the preferred minimum for DES, but recognize that earlier surgery may be necessary with appropriate risk communication and management.

7. A 70-year-old man is referred to vascular medicine for management of intermittent claudication limiting him to 200 meters of level walking. His ABI (ankle-brachial index) is 0.58 on the right. He undergoes echocardiography as part of his workup, which reveals an ejection fraction of 45% with grade II diastolic dysfunction and mildly elevated filling pressures, consistent with HFpEF (heart failure with preserved ejection fraction). He has no prior decompensated heart failure hospitalizations. His medications are aspirin, amlodipine, and atorvastatin. The referring physician has recommended starting cilostazol 100 mg twice daily for his claudication. Which of the following represents the most appropriate management response and correctly identifies the relevant pharmacological contraindication?

A) Cilostazol is contraindicated in this patient because of his HFpEF; cilostazol inhibits phosphodiesterase type 3 (PDE3) in cardiac myocytes as well as in platelets and vascular smooth muscle, raising myocardial cAMP (cyclic AMP) and producing inotropic and proarrhythmic effects; long-term PDE3 inhibition in chronic heart failure has been associated with increased mortality in clinical trials of the milrinone class, and the cilostazol prescribing information carries a formal contraindication for heart failure of any severity, including HFpEF; supervised exercise therapy and evaluation for peripheral revascularization are the appropriate initial approaches for claudication in this patient.
B) Cilostazol can be safely initiated at a reduced dose of 50 mg twice daily in patients with HFpEF when ejection fraction is above 40%; the heart failure contraindication applies only to patients with HFrEF (heart failure with reduced ejection fraction, EF below 40%) because the inotropic risk from PDE3 inhibition is relevant only in the context of systolic dysfunction; at an EF of 45%, the cardiac PDE3 inhibition from cilostazol does not carry the mortality risk observed in systolic heart failure trials.
C) Cilostazol is acceptable in this patient because his HFpEF is asymptomatic and he has never been hospitalized for heart failure decompensation; the FDA contraindication for cilostazol in heart failure applies to patients with symptomatic (NYHA Class II or above) heart failure, not to incidentally discovered diastolic dysfunction on echocardiography; initiation at standard dose is appropriate with monitoring of symptoms.
D) Cilostazol should be initiated as recommended but at a reduced dose of 50 mg twice daily because his concurrent amlodipine use — a moderate CYP3A4 inhibitor — will increase cilostazol plasma concentrations by approximately 50%; this dose adjustment avoids supratherapeutic levels that could produce cardiac PDE3 inhibition sufficient to trigger arrhythmias, while still providing effective antiplatelet and vasodilatory benefit for his claudication.
E) Cilostazol is appropriate for this patient's claudication; HFpEF with preserved ejection fraction represents fundamentally different pathophysiology than systolic heart failure and does not carry the same risk from PDE3 inhibition; the mortality signal observed with milrinone in heart failure trials was specific to systolic dysfunction with reduced EF and does not extrapolate to diastolic dysfunction; initiating cilostazol at standard dose is safe in confirmed HFpEF.

ANSWER: A

Rationale:

Cilostazol is a selective PDE3 (phosphodiesterase type 3) inhibitor that inhibits cAMP degradation in platelets and vascular smooth muscle cells — producing its desired antiplatelet and vasodilatory effects — but also in cardiac myocytes, where elevated cAMP produces positive inotropic and chronotropic effects with potential for increased arrhythmia and adverse myocardial remodeling. The long-term inodilator PDE3 inhibitors milrinone and enoximone demonstrated significantly increased mortality in chronic heart failure trials despite short-term hemodynamic improvement, establishing the class-effect risk of sustained cardiac PDE3 inhibition. The cilostazol FDA prescribing information carries a formal contraindication in heart failure of any severity — not limited to reduced ejection fraction, not limited to symptomatic or hospitalized patients, and not mitigated by preserved ejection fraction. This patient's echocardiographically confirmed HFpEF with elevated filling pressures satisfies the contraindication, regardless of the absence of prior hospitalization or overt symptoms. The appropriate alternatives for claudication management in this patient are supervised exercise therapy (which has Level IA evidence for improving walking distance in PAD) and referral for vascular surgery or endovascular revascularization evaluation.

Option B: Option B is incorrect: the cilostazol contraindication is not restricted to HFrEF (EF below 40%); the prescribing information specifies any severity of heart failure, including HFpEF; the 50 mg dose reduction does not create a safe window in heart failure.
Option C: Option C is incorrect: the contraindication applies to any heart failure diagnosis, not only symptomatic NYHA Class II or above; echocardiographically confirmed HFpEF with elevated filling pressures constitutes heart failure for purposes of this contraindication, regardless of hospitalization history.
Option D: Option D is incorrect: amlodipine is not a moderate CYP3A4 inhibitor — it is a CYP3A4 substrate with weak inhibitory effects that are not clinically significant for cilostazol dosing; dose reduction to 50 mg twice daily is recommended with strong CYP3A4 inhibitors (ketoconazole, itraconazole, certain macrolides), not with amlodipine; more importantly, even with dose adjustment, cilostazol is contraindicated in this patient's heart failure.
Option E: Option E is incorrect: the cilostazol contraindication explicitly covers heart failure of any severity and does not distinguish between HFpEF and HFrEF; the prescribing information does not make this distinction; the class-based mortality risk from cardiac PDE3 inhibition is not proven absent in diastolic dysfunction and the contraindication reflects the precautionary class-effect principle.

8. A 61-year-old man with a drug-eluting stent placed 3 months ago for an NSTEMI (non-ST-elevation myocardial infarction) is on clopidogrel 75 mg daily and aspirin 81 mg. He is a CYP2C19 extensive metabolizer by prior pharmacogenomic testing. He develops upper GI (gastrointestinal) symptoms and his gastroenterologist starts omeprazole 20 mg daily for empiric gastroprotection. The cardiologist is notified and reviews the regimen. Which of the following best describes the cardiologist's appropriate recommendation and the clinical rationale?

A) No change is needed; the drug interaction between omeprazole and clopidogrel is pharmacokinetically modest and has not been shown to increase MACE (major adverse cardiovascular events) in large randomized trials; the gastroprotective benefit of omeprazole in a patient on dual antiplatelet therapy outweighs the theoretical pharmacokinetic concern; continuing both drugs at current doses is appropriate.
B) Switch clopidogrel to ticagrelor 90 mg twice daily and continue omeprazole; ticagrelor's direct-acting mechanism is unaffected by CYP2C19 inhibition, so the pharmacokinetic interaction with omeprazole is eliminated entirely; this substitution preserves both adequate P2Y12 inhibition and GI protection without requiring a PPI change.
C) Omeprazole should be discontinued entirely; PPI use in post-PCI patients on clopidogrel increases 30-day stent thrombosis risk by 40% based on pharmacokinetic modeling; no gastroprotective agent is safe to combine with clopidogrel; GI symptoms should be managed with antacids alone until the mandatory 12-month DAPT period is completed.
D) Switch omeprazole to pantoprazole; omeprazole is a significant CYP2C19 inhibitor that reduces clopidogrel active thiol metabolite generation by competing for and inhibiting the enzyme responsible for clopidogrel's key bioactivation step; pantoprazole has minimal CYP2C19 inhibitory activity at therapeutic doses and is the preferred PPI when clopidogrel and a PPI must be co-prescribed; this change is particularly important for this CYP2C19 extensive metabolizer, as the degree of inhibition from omeprazole is clinically meaningful even when baseline CYP2C19 function is normal.
E) Switch clopidogrel to prasugrel 10 mg daily and continue omeprazole; prasugrel's bioactivation is less CYP2C19-dependent than clopidogrel's and is not meaningfully affected by omeprazole's CYP2C19 inhibition; this agent substitution addresses the pharmacogenomic vulnerability without requiring a change to the GI regimen.

ANSWER: D

Rationale:

Omeprazole and esomeprazole are significant CYP2C19 substrates and inhibitors; by competing for CYP2C19 and inhibiting the enzyme, they reduce the generation of clopidogrel's active thiol metabolite at the second (and to a lesser extent the first) hepatic bioactivation step where CYP2C19 plays the dominant role. This pharmacokinetic interaction reduces clopidogrel-mediated platelet inhibition and was identified in multiple dedicated pharmacokinetic studies, prompting FDA guidance recommending against the combination of clopidogrel with omeprazole or esomeprazole. Notably, this interaction is clinically meaningful even in CYP2C19 extensive metabolizers (as this patient is), because omeprazole's inhibitory effect reduces active metabolite generation regardless of the patient's baseline CYP2C19 genotype — the enzyme is partially inhibited, reducing its capacity to bioactivate clopidogrel below the level expected even for an extensive metabolizer. Pantoprazole has minimal CYP2C19 inhibitory activity at therapeutic doses and is the guideline-recommended PPI substitute when a PPI must be co-prescribed with clopidogrel. Rabeprazole is another acceptable alternative. The practical recommendation is therefore to switch from omeprazole to pantoprazole while maintaining clopidogrel.

Option A: Option A is incorrect: while large randomized outcome trials have not definitively shown increased MACE with the combination (a finding debated in the literature), pharmacokinetic studies consistently demonstrate reduced clopidogrel active metabolite exposure with omeprazole; FDA guidance and ACC/AHA recommendations support avoiding omeprazole/esomeprazole with clopidogrel when an alternative PPI is available.
Option B: Option B is incorrect: switching clopidogrel to ticagrelor solely to avoid a PPI interaction is pharmacologically sound but represents an unnecessary escalation of antiplatelet potency; the simpler, guideline-supported solution is substituting pantoprazole for omeprazole while maintaining clopidogrel.
Option C: Option C is incorrect: omeprazole discontinuation without gastroprotective replacement in a patient on dual antiplatelet therapy is not the recommended approach; patients on DAPT have increased GI bleeding risk, and PPI co-prescription (with an appropriate agent) is recommended for those with GI risk factors; GI symptoms on DAPT warrant appropriate management.
Option E: Option E is incorrect: while prasugrel bioactivation is less CYP2C19-dependent, switching the P2Y12 inhibitor class rather than substituting the PPI with a CYP2C19-neutral option (pantoprazole) is a more complex intervention than necessary; prasugrel carries its own contraindications and increased bleeding risk compared to clopidogrel.

9. A 58-year-old man had a STEMI (ST-elevation myocardial infarction) 12 months ago treated with drug-eluting stent placement and has completed 12 months of dual antiplatelet therapy (DAPT) with ticagrelor 90 mg twice daily and aspirin 81 mg without any bleeding events. His medical history includes diabetes mellitus, a prior myocardial infarction 5 years ago, and current smoking. His ejection fraction is 48%. His DAPT Score is calculated at 3. He returns for his 12-month follow-up and asks his cardiologist whether he should continue DAPT. Which of the following best represents the appropriate application of the DAPT Score to this patient's management?

A) A DAPT Score of 3 is below the threshold of 5 required to recommend DAPT extension; scores below 5 indicate that the ischemic risk reduction from extended DAPT does not outweigh the cumulative bleeding risk of prolonged dual therapy; DAPT should be de-escalated to aspirin monotherapy at 12 months.
B) The DAPT Score cannot be applied to patients who received ticagrelor, because the score was derived and validated exclusively in clopidogrel-treated patients in the DAPT trial; applying the score to ticagrelor-treated patients overestimates the ischemic benefit of continuation and underestimates the bleeding risk; extended ticagrelor should not be guided by DAPT Score.
C) A DAPT Score of 3 — which equals or exceeds the validated threshold of 2 — indicates that this patient is predicted to derive net ischemic benefit from DAPT extension beyond 12 months; given that he has tolerated 12 months without bleeding, extension of DAPT is recommended; ticagrelor may be continued or a de-escalation to clopidogrel considered for tolerability and cost, while aspirin is maintained.
D) The DAPT Score should not be applied because this patient has multiple high-risk features; DAPT Score is validated only in low-to-intermediate risk patients; for high-risk patients (prior MI, diabetes, reduced EF), indefinite triple antiplatelet therapy (aspirin plus two P2Y12 inhibitors) provides better secondary prevention than score-guided extension of standard DAPT.
E) A DAPT Score of 3 supports a recommendation to add vorapaxar to his current aspirin monotherapy regimen (after stopping ticagrelor at 12 months); DAPT Score scores of 2 to 4 specifically identify patients who would benefit from transition to OAC (oral anticoagulant) plus aspirin rather than continued DAPT extension, particularly in post-MI patients with left ventricular dysfunction.

ANSWER: C

Rationale:

The DAPT Score was derived from the DAPT trial and validated to identify patients who would derive net clinical benefit from DAPT prolongation beyond 12 months after coronary stent implantation. The scoring system assigns positive points for features predicting ischemic benefit from continuation (younger age, diabetes, current smoker, prior PCI or MI, CHF or EF below 30%, vein graft stenting, drug-eluting stent specific variables) and negative points for age above 75 years, which predicts disproportionate bleeding risk with prolonged therapy. The validated action threshold is a score of 2 or above, at which point the ischemic benefit of DAPT extension outweighs the associated bleeding risk in patients who have already tolerated 12 months without bleeding. This patient's DAPT Score of 3 exceeds the threshold of 2, supporting DAPT extension. His multiple high-risk features — active smoking, diabetes mellitus, prior MI — contributed to this score and are precisely the clinical characteristics that predict ischemic benefit from longer P2Y12 inhibition. The cardiologist may continue ticagrelor at the approved 60 mg twice daily secondary prevention dose (approved for patients more than 1 year post-MI) or discuss de-escalation to clopidogrel for tolerability, cost, or if dyspnea was a concern, while maintaining aspirin.

Option A: Option A is incorrect: the DAPT Score threshold for recommending extension is 2, not 5; a score of 3 clearly exceeds this threshold; the correct interpretation is that extension is favored, not that aspirin monotherapy should begin.
Option B: Option B is incorrect: while the DAPT trial primarily studied clopidogrel and paclitaxel-eluting stents, the DAPT Score is used clinically as a risk stratification tool across the contemporary stent and P2Y12 inhibitor landscape; guidelines apply the score broadly and do not restrict its use to clopidogrel-treated patients.
Option D: Option D is incorrect: there is no validated triple antiplatelet therapy regimen combining aspirin plus two P2Y12 inhibitors for secondary prevention; such a combination has not been tested in randomized trials and would carry unacceptable bleeding risk; the DAPT Score is applicable across risk categories including high-risk patients.
Option E: Option E is incorrect: the DAPT Score does not recommend vorapaxar addition or OAC-plus-aspirin transition; it informs the decision of whether to extend standard DAPT (P2Y12 inhibitor plus aspirin) beyond 12 months; the interpretive framework described in this option is fabricated.

10. A 64-year-old man with a drug-eluting stent placed 4 months ago for a STEMI (ST-elevation myocardial infarction) is on ticagrelor 90 mg twice daily and aspirin 81 mg. He is now diagnosed with a resectable sigmoid colon cancer confirmed on colonoscopy and CT staging. The colorectal surgeon recommends urgent (not emergent) laparoscopic sigmoid colectomy within the next 3 days due to near-obstructive symptoms. The surgeon asks the cardiologist whether the surgery can proceed after only 3 days of ticagrelor hold rather than the standard 5 days. Which of the following best characterizes the clinical risk framework and the appropriate management approach for this patient?

A) Surgery should proceed after 3 days of ticagrelor hold; platelet function testing (VerifyNow P2Y12 assay) should be performed on the day of surgery, and if residual P2Y12 inhibition is less than 50%, surgery can proceed safely regardless of the days of hold elapsed; functional platelet testing overrides the days-based hold recommendation in urgent surgical situations.
B) The 3-day hold is shorter than the recommended 5-day interval and carries a higher risk of surgical bleeding than a full 5-day hold; the cardiology and surgical teams must weigh the risk of proceeding with incomplete platelet function recovery against the clinical urgency of the near-obstructive cancer; if surgery is deemed medically necessary within 3 days, the patient and team should proceed with informed consent that surgical bleeding risk is elevated, aspirin should be continued, and the surgical team should be prepared for possible increased intraoperative bleeding; the stent thrombosis risk during a 3-day hold at 4 months post-DES, while not negligible, is lower than it would be in the first 3 months.
C) The surgery must be deferred until 5 full days of ticagrelor hold have elapsed without exception; the 5-day recommendation is based on the time required for near-complete platelet pool replacement and is a hard minimum that cannot be shortened for any elective or urgent (non-emergent) procedure; proceeding at 3 days constitutes a deviation from standard of care that exposes the surgeon to liability.
D) Ticagrelor should be held for 3 days and cangrelor IV bridging initiated immediately to maintain P2Y12 coverage during the shortened hold interval; cangrelor is stopped 1 hour before surgical incision; this approach simultaneously prevents stent thrombosis during the pre-operative hold and allows surgery to proceed at 3 days with acceptable bleeding risk.
E) Surgery can proceed immediately without any ticagrelor hold because near-obstructive colon cancer represents a surgical emergency; emergent surgical indications eliminate the pre-operative antiplatelet hold requirement; aspirin should also be stopped 24 hours before surgery to minimize all antiplatelet effects during the procedure.

ANSWER: B

Rationale:

This case presents a genuine conflict between two risks: the elevated surgical bleeding risk from a 3-day ticagrelor hold (shorter than the standard 5-day recommendation) versus the clinical urgency of a near-obstructive resectable colon cancer requiring timely surgery. The correct framework is shared clinical decision-making — not a rigid rule in either direction. The 5-day hold recommendation for ticagrelor is based on the time required for sufficient platelet function recovery to achieve surgical hemostasis in most patients; at 3 days, platelet function has partially recovered but likely not to the level achievable at 5 days, meaning intraoperative and postoperative bleeding risk is higher than it would be with a full hold. However, near-obstruction from colon cancer creates a legitimate urgency that the standard 5-day guidance did not contemplate as a rigid floor; guidelines acknowledge that "when surgery cannot be deferred, the decision to continue or hold antiplatelet therapy requires cardiology and surgical co-management with explicit discussion of stent thrombosis risk." At 4 months post-DES, the stent thrombosis risk during a short antiplatelet hold, while not zero, is substantially lower than it would be in the first 6 to 8 weeks. Aspirin continuation is appropriate. The informed decision to proceed at 3 days with elevated bleeding awareness is a reasonable clinical judgment, not a clear standard-of-care deviation.

Option A: Option A is incorrect: while platelet function testing can provide objective data on residual P2Y12 inhibition, it does not override the judgment framework; a single-threshold cutoff of 50% residual inhibition as a go/no-go criterion is not a validated or guideline-endorsed protocol for perioperative management.
Option C: Option C is incorrect: the 5-day recommendation is a guideline-based best practice, not an immutable legal standard; urgent surgical situations require individualized risk-benefit assessment; characterizing a 3-day hold as per se a standard-of-care deviation misrepresents how perioperative guidelines are applied.
Option D: Option D is incorrect: cangrelor bridging is used to maintain P2Y12 inhibition up to the time of surgery in patients who need coverage during the pre-operative hold (typically very-early-post-stent patients where stopping P2Y12 is very high risk); bridging during the hold interval and then stopping at incision does not reduce surgical bleeding risk at the time of the procedure — the patient still goes to surgery under the same platelet function status as if the hold alone had been performed; bridging prevents thrombosis during the hold but does not address bleeding risk at the surgical site.
Option E: Option E is incorrect: near-obstruction, while urgent, is not an absolute surgical emergency in the same category as life-threatening hemorrhage or intestinal perforation; non-emergency procedures retain the standard recommendation to optimize antiplatelet management; stopping aspirin 24 hours before is not the guideline recommendation (5 to 7 days for high-risk surgery) and removes a protective agent during the early post-stent period.

11. A 69-year-old man with persistent atrial fibrillation (AF) underwent PCI (percutaneous coronary intervention) with drug-eluting stent placement 6 weeks ago for an NSTEMI (non-ST-elevation myocardial infarction) and was placed on triple therapy: apixaban 5 mg twice daily, clopidogrel 75 mg daily, and aspirin 81 mg. He now presents with melena and a hemoglobin of 9.1 g/dL (down from 13.4 g/dL at discharge). Upper endoscopy reveals a 1.2 cm duodenal ulcer with a visible vessel. After successful endoscopic hemostasis, the gastroenterologist asks the cardiologist to recommend an adjusted antithrombotic regimen going forward. The patient remains hemodynamically stable and the ulcer has been treated. Which of the following best represents the appropriate adjustment to his antithrombotic regimen and the correct rationale?

A) Discontinue all antiplatelet agents and maintain apixaban alone; the AUGUSTUS trial demonstrated that antiplatelet therapy adds no ischemic benefit to anticoagulation in AF-PCI patients beyond 6 weeks; apixaban provides both stroke prevention and some antiplatelet activity through its effects on thrombin-mediated platelet activation; reducing to anticoagulant monotherapy eliminates the synergistic GI bleeding risk of combined therapy.
B) Discontinue apixaban and maintain dual antiplatelet therapy (DAPT) with aspirin and clopidogrel; this patient's stent at 6 weeks is at the highest-risk period for stent thrombosis, making P2Y12 inhibition the priority; aspirin and clopidogrel together provide sufficient secondary prevention for both the stent and AF-related stroke through their antiplatelet effects on platelet-fibrin thrombi.
C) Discontinue clopidogrel and maintain apixaban plus aspirin; the P2Y12 inhibitor is the most expendable component at 6 weeks post-stent because aspirin and anticoagulation together provide adequate stent thrombosis and stroke protection; clopidogrel's contribution to bleeding risk exceeds its antiplatelet benefit at this time point.
D) Continue all three agents (apixaban, clopidogrel, and aspirin) with addition of a high-dose PPI; the patient is only 6 weeks post-DES, which is within the highest-risk window for stent thrombosis; the correct response to GI bleeding on triple therapy is aggressive ulcer management with high-dose PPI rather than antithrombotic dose reduction, which carries unacceptable stent and stroke thrombosis risk at this early time point.
E) Discontinue aspirin and maintain dual therapy with apixaban plus clopidogrel; aspirin is the component whose removal is most supported by evidence — the AUGUSTUS trial demonstrated that adding aspirin to OAC plus P2Y12 inhibitor doubled clinically relevant bleeding without reducing the composite ischemic endpoint; at 6 weeks the initial highest-risk stent thrombosis window is substantially passed, and OAC plus P2Y12 inhibitor (without aspirin) maintains both AF stroke prevention and meaningful post-stent antiplatelet protection while substantially reducing ongoing GI bleeding risk.

ANSWER: E

Rationale:

This patient has now had a clinically significant GI bleed on triple therapy, providing an unambiguous indication to reduce his antithrombotic regimen. The key question is which component to remove. The AUGUSTUS trial directly addressed this: in AF patients with recent ACS or PCI receiving OAC plus P2Y12 inhibitor, adding aspirin doubled clinically relevant bleeding events without reducing the composite ischemic endpoint (death, MI, or stroke). Aspirin is therefore the component that contributes disproportionately to bleeding risk relative to ischemic benefit in this combined regimen. Removing aspirin while maintaining apixaban plus clopidogrel preserves both AF stroke prevention (apixaban) and post-stent P2Y12 inhibition (clopidogrel) — the two components with distinct, non-redundant indications — while eliminating the agent whose incremental antithrombotic benefit in this specific combination is outweighed by its bleeding contribution. At 6 weeks post-DES, the highest-risk period for acute stent thrombosis (first 30 days) has largely passed, making this an appropriate transition point to dual therapy. A PPI should be added and maintained for gastric protection on the new regimen.

Option A: Option A is incorrect: anticoagulant monotherapy without a P2Y12 inhibitor after drug-eluting stent placement at 6 weeks carries an unacceptably high stent thrombosis risk; P2Y12 inhibition is essential during the post-stent endothelialization period; apixaban does not provide meaningful antiplatelet protection through thrombin-mediated platelet activation blockade at standard anticoagulant doses.
Option B: Option B is incorrect: discontinuing the OAC (apixaban) in an AF patient with CHA₂DS₂-VASc score sufficient to warrant anticoagulation is not appropriate; AF-related cardioembolic stroke is driven by fibrin-based left atrial thrombus and requires anticoagulation — DAPT alone cannot substitute; OAC is the irreplaceable component for AF stroke prevention.
Option C: Option C is incorrect: removing the P2Y12 inhibitor (clopidogrel) while maintaining aspirin plus OAC reverses the AUGUSTUS evidence — the data showed OAC plus P2Y12 inhibitor (not OAC plus aspirin without P2Y12) is the preferred dual combination; P2Y12 inhibition is more important than aspirin for post-PCI stent protection, and aspirin adds more bleeding risk than P2Y12 inhibitor in this combination.
Option D: Option D is incorrect: continuing triple therapy after an endoscopically confirmed bleeding episode with a significant drop in hemoglobin is not appropriate; while PPI therapy is important for ulcer healing, it does not resolve the excess antithrombotic burden that caused the bleed; aspirin should be removed per AUGUSTUS evidence.